Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 728-733

  Ong, Kwok Leung ^a   Wu, Ben J ^a   Cheung, Bernard M Y ^b   Barter, Philip J ^a,c   Rye, Kerry Anne ^a,c,d  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bilirubin; Cardiovascular risk; Heme oxygenase; NHANES; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; C REACTIVE PROTEIN; CERIVASTATIN; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEME OXYGENASE 1; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SELF REPORT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 82955187697     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.094     Document Type: Article

References (30)

1. Lin J.P., Vitek L., Schwertner H.A. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010, 56:1535-1543.
2. Platt J.L., Nath K.A. Heme oxygenase: protective gene or Trojan horse. Nat Med 1998, 4:1364-1365.
3. Farombi E.O., Surh Y.J. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol 2006, 39:479-491.
4. Sedlak T.W., Saleh M., Higginson D.S., Paul B.D., Juluri K.R., Snyder S.H. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 2009, 106:5171-5176.
5. Lin L.Y., Kuo H.K., Hwang J.J., et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009, 203:563-568.
6. Schwertner H.A., Jackson W.G., Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994, 40:18-23.
7. Perlstein T.S., Pande R.L., Beckman J.A., Creager M.A. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008, 28:166-172.
8. Perlstein T.S., Pande R.L., Creager M.A., Weuve J., Beckman J.A. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008, 121:781-788.
9. Stocker R., Perrella M.A. Heme oxygenase-1: a novel drug target for atherosclerotic diseases?. Circulation 2006, 114:2178-2189.
10. Durante W. Targeting heme oxygenase-1 in vascular disease. Curr Drug Targets 2010, 11:1504-1516.
11. Wu B.J., Midwinter R.G., Cassano C., et al. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009, 29:1537-1542.
12. Lee T.S., Chang C.C., Zhu Y., Shyy J.Y. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004, 110:1296-1302.
13. Hsu M., Muchova L., Morioka I., Wong R.J., Schröder H., Stevenson D.K. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun 2006, 343:738-744.
14. Ali F., Hamdulay S.S., Kinderlerer A.R., et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007, 5:2537-2546.
15. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS): National Health and Nutrition Examination Survey questionnaire, examination protocol and laboratory protocol. Hyattsville, Maryland: United States Department of Health and Human Services, Centers for Disease Control and Prevention, 1999-2008. Available at: accessed (11.02.11). http://www.cdc.gov/nchs/nhanes.htm.
16. Hwang H.J., Kim S.H. Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin Chim Acta 2010, 411:1496-1501.
17. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and ß-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. Zhou Q., Liao J.K. Pleiotropic effects of statins - basic research and clinical perspectives. Circ J 2010, 74:818-826.
20. Shishehbor M.H., Aviles R.J., Brennan M.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675-1680.
21. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
22. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
23. Muchova L., Wong R.J., Hsu M., et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007, 85:800-810.
24. Kawata S., Yamasaki E., Nagase T., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84:886-891.
25. Ryter S.W., Tyrrell R.M. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radic Biol Med 2000, 28:289-309.
26. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010, 51:1546-1553.
27. Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010, 105:69-76.
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
29. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
30. Bao W., Song F., Li X., et al. Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One 2010, 5:e12371.